MarkABoydMD

PubMed

• 5 citations
  Resident Perceptions of Competency and Comfort Before and After Telemedicine-ICU Implementation.
  Alexa Summe, Laura Foor, Lauren Hoeck, Kristen Campbell, Mark F. Boyd, Mary Ann Barnes> ;Southern Medical Journal. 2018 Jun 1
• 3 citations
  Sexual transmission of HIV and the law: an Australian medical consensus statement
  Mark A. Boyd, David A. Cooper, Elizabeth A Crock, Levinia Crooks, Michelle L. Giles, Andrew E. Grulich, Sharon R Lewin, David Nolan, Trent Yarwood> ;The Medical Journal of Australia. 2016 Nov 7
• 12 citations
  Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
  Edward Patrick Lam, Cecilia L. Moore, Eduardo Gotuzzo, Chidi Nwizu, Adeeba Kamarulzaman, Ploenchan Chetchotisakd, Jean van Wyk, Hedy Teppler, Nagalingeswaran Kumarasam...> ;AIDS Research and Human Retroviruses. 2016 Sep 1
• 16 citations
  Which HIV patients should be screened for osteoporosis: an international perspective.
  Elena Alvarez, Waldo H. Belloso, Mark A. Boyd, Ahmet Çağkan İnkaya, Evelyn Hsieh, Andrew Kambugu, Greg Kaminski, Esteban Martínez, Hans Jürgen Stellbrink, Sharon Walms...> ;Current Opinion in HIV and AIDS. 2016 May 1
• 2 citations
  Tenofovir alafenamide: safer, but questions remain
  Mark A. Boyd, David A. Cooper> ;The Lancet. HIV. 2016 Apr 1
• The LATTE study: a provocative brew.
  Mark A. Boyd, David A. Cooper> ;The Lancet. Infectious Diseases. 2015 Oct 1
• Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications.
  Wilkie M, Lau A, Vlatkovic N, Jones T, Boyd M> ;Lancet. 2015-02-26
• 5 citations
  Is it time to rethink syphilis control
  Mark A. Boyd, Basil Donovan, Garrett Prestage, Marcus Y Chen, Kathy Petoumenos, Richard Gray, Rebecca Guy, Geraint B. Rogers, Chris Bourne, Jeffrey D. Klausner> ;Clinical Infectious Diseases. 2015 Jan 15
• 16 citations
  Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
  Hila Haskelberg, Patrick W. G. Mallon, Jennifer F Hoy, Janaki Amin, Cecilia L. Moore, Praphan Phanuphak, Samuel Ferret, Waldo H. Belloso, Mark A. Boyd, David A. Cooper...> ;Journal of Acquired Immune Deficiency Syndromes. 2014 Oct 1
• 1 citations
  A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy
  Andrew D. Revell, Mark A. Boyd, D. Wang, Sean Emery, Brian Gazzard, Peter Reiss, A.I. van Sighem, Julio S. G. Montaner, H C Lane, B. A. Larder> ;HIV Medicine. 2014 Apr 15
• 19 citations
  Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.
  Stephen T. Wright, Jennifer F Hoy, Brian P Mulhall, Catherine C O'Connor, Kathy Petoumenos, Tim R H Read, Don Smith, Ian Woolley, Mark A. Boyd> ;Journal of Acquired Immune Deficiency Syndromes. 2014 May 1
• 5 citations
  Recent trends in early stage response to combination antiretroviral therapy in Australia.
  Hamish McManus, Jennifer F Hoy, Ian Woolley, Mark A. Boyd, Mark D Kelly, Brian P Mulhall, Norman Roth, Kathy Petoumenos, Matthew Law> ;Antiviral Therapy. 2014 Apr 4
• 3 citations
  SPRING-2 the future of antiretroviral therapy.
  Mark A. Boyd, David A. Cooper> ;The Lancet. Infectious Diseases. 2013 Nov 1
• 33 citations
  Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
  Allison Martin, Cecilia L. Moore, Patrick W. G. Mallon, Jennifer F Hoy, Sean Emery, Waldo H. Belloso, Praphan Phanuphak, Samuel Ferret, David A. Cooper, Mark A. Boyd> ;AIDS. 2013 Sep 24
• 4 citations
  Antiretroviral therapy: dolutegravir sets SAIL(ING)
  Mark A. Boyd, Basil Donovan> ;Lancet. 2013 Aug 24
• 127 citations
  Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 i...
  Mark A. Boyd, N. Kumarasamy, Cecilia L. Moore, Chidi Nwizu, M. H. Losso, Lerato Mohapi, Allison Martin, Stephen J. Kerr, Annette H. Sohn, Hedy Teppler, O Van De Steen,...> ;Lancet. 2013 Jun 15
• 13 citations
  Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.
  James Jansson, David Wilson, Andrew Carr, Kathy Petoumenos, Mark A. Boyd> ;AIDS. 2013 May 15
• 16 citations
  Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience
  Stephen T. Wright, Kathy Petoumenos, Mark A. Boyd, Andrew Carr, Sandra Downing, Catherine C O'Connor, Miriam Grotowski, Matthew Law> ;HIV Medicine. 2013 Apr 1
• 12 citations
  Optimisation of HIV care and service delivery: doing more with less.
  Mark A. Boyd, David A. Cooper> ;Lancet. 2012 Nov 24
• 5 citations
  Pharmacokinetics and 48 Week Efficacy of Adjusted Dose Indinavir/Ritonavir in Rifampicin-Treated HIV/Tuberculosis-Coinfected Patients: A Pilot Study
  Anchalee Avihingsanon, Jasper van der Lugt, Umaporn Singphore, Meena Gorowara, Mark A. Boyd, Jintanat Ananworanich, Praphan Phanuphak, David M. Burger, Kiat Ruxrungtham> ;AIDS Research and Human Retroviruses. 2012 Sep 20
• STRETCHing delivery of HIV health services
  Mark A. Boyd, Lerato Mohapi> ;Lancet. 2012 Sep 8
• 17 citations
  A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
  Dianne Carey, Sarah Pett, Mark Bloch, Handan Wand, Karen MacRae, Kate Beileiter, John E. Ray, Mark A. Boyd, Sean Emery, David A. Cooper> ;Journal of Acquired Immune Deficiency Syndromes. 2012 Jun 1
• 5 citations
  Dolutegravir--a promising antiretroviral in development.
  Mark A. Boyd> ;The Lancet. Infectious Diseases. 2012 Feb 1
• 49 citations
  Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell Response: A...
  Helen Byakwaga, Mark D Kelly, Damian F. J. Purcell, Martyn A. French, Janaki Amin, Sharon R Lewin, Hila Haskelberg, Anthony D. Kelleher, Roger Garsia, Mark A. Boyd, Da...> ;The Journal of Infectious Diseases. 2011 Nov 15
• 1 citations
  Overly Optimistic Forecasts for the Impact of Treatment of HIV Prevention for Men Who Have Sex With Men
  David Wilson, Andrew E. Grulich, Mark A. Boyd> ;Clinical Infectious Diseases. 2011 Sep 15
• Join now to see all